Loading...
Coherus Oncology, Inc.
CHRS•NASDAQ
Healthcare
Biotechnology
$1.75
$0.15(9.06%)
U.S. Market is Open • 10:05Coherus Oncology, Inc. (CHRS) AI-Powered Stock Analysis
See how Coherus Oncology, Inc. scores across key metrics like financial growth, valuation, and market position using AI-driven evaluation.
Model Information
The AI Stock Analysis Model is provided for informational purposes only and should not be considered financial advice. We are continously improving this model to increase accuracy and performance.Read our Full DisclaimerCoherus Oncology, Inc. (CHRS) Stock Overall Grade
Coherus Oncology, Inc.’s grade based on a comprehensive AI analysis of financial metrics, growth potential, and market position.
Z
Grade Breakdown by Metric
See how each financial and market factor contributes to Coherus Oncology, Inc.'s overall stock rating.
Forecast
C+Score
55/100Financial Growth
BScore
60/100Fundamental Growth
BScore
69/100Key Ratios
AScore
82/100Sector Comparison
A+Score
100/100Industry Comparison
C+Score
50/100S&P 500 Benchmark
A+Score
94/100Analyst Consensus
BScore
63/100Coherus Oncology, Inc. (CHRS) AI-Powered Stock Analysis
This asset demonstrates Good performance with an overall Forecast Score of 55/100 (C+), reflecting weak confidence in its potential. Financial Growth (60/100, B) and Fundamental Growth (69/100, B) highlight its stability, while Key Ratios (82/100, A) and Sector Comparison (100/100, A+) indicate solid positioning. Compared to broader benchmarks like the S&P 500 (94/100, A+), it shows competitive strength. Analyst Consensus (63/100,B) suggests High divergence in outlook.Component Analysis Explained
Understand the key factors behind each Coherus Oncology, Inc. stock grade, including financials, comparisons, and forecasts.